The role of Ca 2+ sensitization induced by a Ca 2+ -independent myosin light chain kinase (MLCK) in hypertension has not been determined. The aim of this study was to clarify the role of possible Ca 2+ -independent MLCK activity in hypertension.
Introduction
Smooth muscle contraction is activated primarily by phosphorylation at Ser 19 of the 20 kDa regulatory light chains of myosin II (RLC 20 ), 1 which is controlled by the opposing activities of myosin light chain kinase (MLCK) 2 and myosin light chain phosphatase (MLCP). 3 The amplitude of contraction can be affected by any change in the ratio of MLCK:MLCP activity. MLCK activity is dependent on Ca 2+ -calmodulin; hence, the intracellular Ca 2+ concentration ([Ca 2+ ] i ) is the primary determinant of smooth muscle contraction. 4 However, both contractile force development and RLC 20 4 or by activation of extracellular-regulated kinase-mediated caldesmon phosphorylation. 5 Inhibition of MLCP can occur either directly by phosphorylation of the myosin phosphatase target subunit (MYPT1) of MLCP 6 or indirectly via phosphorylation of a protein kinase C (PKC)-potentiated phosphatase inhibitor protein of 17 kDa (CPI-17). 7 Another possible mechanism for Ca 2+ sensitization also exists.
Ca 2+ -independent MLCK activity has been identified. When microcystin-LR, a type 1 and 2A phosphatase inhibitor, is applied to permeabilized smooth muscle strips in Ca 2+ -free media, a Ca 2+ -independent sustained contraction is observed, which cannot be attributed to traditional MLCK activity. 8 -10 This Ca 2+ -independent contraction is accompanied by di-phosphorylation of RLC 20 at Ser 19 and Thr 18 . 10 Similar results have been obtained with a number of different smooth muscle tissues and with other type 1 and 2A phosphatase inhibitors, okadaic acid, and calyculin A, 11 -13 suggesting a common mechanism. Since MLCK is absolutely dependent on Ca 2+ and, at physiological levels of the kinase, is specific for phosphorylation at Ser 19 , the kinase responsible is clearly not MLCK itself. 14 Previous reports have suggested several candidates for this Ca 2+ -independent MLCK, including rho-associated kinase (ROCK), 15 PKC, 16 mitogenactivated protein kinase (MAPK)-activated protein kinase-2, 17 MAPK-activated protein kinase-1b, 18 Integrin-linked kinase (ILK), 19 and ZIPK. 8 Phosphorylation of RLC 20 , and di-phosphorylation of the RLC 20 enhances the tension acting on stress fibres in fibroblasts. 23 While RLC 20 monophosphorylation is most commonly observed in smooth muscle tissue in response to physiological contractile stimuli, RLC 20 di-phosphorylation is more commonly observed in pathological situations such as vasospasm. 24, 25 These observations have led to the suggestion that di-phosphorylation of RLC 20 is associated with hypercontractility of vascular smooth muscle. Furthermore, augmented Ca 2+ sensitization has been reported in hypertensive animal models. 26 -28 Although pathological alterations to the sensitivity of the smooth muscle contractile response to Ca 2+ have been hypothesized to underlie many diseases, such as hypertension 29, 30 and vasospasm, 31 the role of Ca 2+ sensitization induced by a Ca 2+ -independent MLCK in hypertension has not been determined and the precise identity of the Ca 2+ -independent MLCK remains controversial. In the present study, we determined that an increased contractile force and di-phosphorylation of RLC 20 caused by a Ca 2+ -independent MLCK occurs in a model of hypertension and, furthermore, that the subcellular mechanism likely involves ZIPK-mediated phosphorylation of MYPT1.
Methods
This investigation confirms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996). All procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Yonsei University College of Medicine.
Tissue preparation and organ bath study
Male spontaneously hypertensive rat (SHR) and Wistar Kyoto rat (WKY) aged 16 -18 weeks were purchased from Japan SLC, Inc., Inasa Production Facility. The mean systolic blood pressures of the SHR and WKY rats measured by the tail-cuff method were 202 + 10 and 145 + 10.5 mmHg, respectively. The rats were killed by decapitation. All mesenteric arteries were excised and placed in a HEPES-Tyrode solution composed of the following (in mmol/L): NaCl, 134; KCl, 5.6; CaCl 2 , 2.5; MgCl 2 , 1; HEPES, 10; glucose, 10. The HEPES-Tyrode solution was continuously aerated with 100% O 2 . The second or third branches of the mesenteric arteries were dissected and ring segments ( 1 mm in length) were prepared. Fat and adventitia were removed mechanically under a binocular microscope, and the endothelium of the arterial ring was removed by gently rubbing the endothelial surface with the edge of a forceps. Removal of endothelium was confirmed by observing the absence of relaxation on challenge with acetylcholine when 70 mmol K + solution (equimolar substitution of Na + with K + )-induced contraction had reached a plateau.
Force was measured as we have previously described. 
RLC 20 phosphorylation measurements
Phosphorylation of the RLC 20 in the SHR and WKY was measured using glycerol-urea minigels as described previously. 34 The vessels were frozen when the contractile response became stable at pCa 9.0, pCa 4.5, and pCa 9.0 with calyculin A.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotting
The expression levels of proteins in non-stretched SHR and WKY mesenteric arteries, the effects of calyculin A on the mono-and di-phosphorylation of the RLC 20 , Thr 697 , and Thr 855 phosphorylation of MYPT1, and CPI-17 phosphorylation were measured by using western blot as described previously. 32 
Immunofluorescence
The expression of protein in the first or second mesenteric branches and di-phosphorylated forms of RLC 20 in the SHR and WKY were measured by the immunofluorescence method using a confocal laser scanning microscope. Non-stretched arteries and vessels after a functional study were fixed with paraformaldehyde embedded in an optimal cutting temperature (Sakura Fine Tec Inc., Torrance, CA, USA) compound and frozen in liquid nitrogen. The frozen sections (10 mm) were cut onto gelatincoated slides, air-dried, and then washed with phosphate-buffered saline (PBS; 137 mmol/L NaCl, 2.7 mmol/L KCl, 10.14 mmol/L Na 2 HPO 4 , 1.76 mmol/L KH 2 PO 4 , 0.05% Tween 20) . After a blockade with blocking solution composed of PBS containing 3% bovine serum albumin and 0.5% Triton X-100, the sections were incubated with primary antibodies in blocking solution overnight in a humidified chamber at room temperature. The specific primary antibodies used are as follows: ZIPK (1:50, Santa Cruz), total MLC (1:100, Sigma), b-actin (1:500, Abcam), and ppMLC (1:100, Cell Signaling, MA, USA). After washing with PBS, sections were incubated with the secondary antibodies for 1 h in the dark. Immunofluorescent signals were viewed using a confocal laser scanning microscope (Carl Zeiss, LSM 510) with oil immersion lens. The specificity of the immunostaining was evaluated by omission of the primary antibody (negative control) and processed as above.
Drugs
The following drugs were used: calyculin A (Enzo Life Science; The general laboratory reagents used were analytical grade or better.
Statistics
All values given in the text are expressed as mean + SEM and were analysed by ANOVA, followed by Tukey's test. Significant differences were taken at the P , 0.05 level. Force was expressed as a relative percentage of the amplitude of the contraction at pCa 4.5.
Results

Calyculin A induces a Ca
21 -independent contraction of b-escin-permeabilized rat mesenteric arterial smooth muscle calphostin-C), and a non-specific, broad-spectrum protein kinase inhibitor (10 25 M staurosporine). As shown in Figure 1 , wortmannin, Y-27632, and calphostin-C were ineffective, whereas staurosporine inhibited the calyculin A-induced contraction. Staurosporine decreased the calyculin A-induced contraction from 59.9 + 5.2% (n ¼ 7, contraction normalized to maximal pCa 4.5-induced contraction) to 6.7 + 6.7% (n ¼ 4, P , 0.01). Y.-E. Cho et al.
The Ca 21 -independent, calyculin A-induced contraction and RLC 20 phosphorylation are augmented in the SHR
To clarify whether the Ca 2+ -independent, calyculin A-induced contraction increases in a hypertensive model, we compared the calyculin A-induced contraction in permeabilized rat mesenteric arterial smooth muscle of SHR and WKY at pCa 9.0. As shown in Figure 2A , the Ca 2+ -independent, calyculin A-induced contraction was concentration dependent. The maximum response was obtained at 1 mM in the SHR and the WKY, but the amplitude of the contraction was greater in the SHR (79.0 + 7.8%, n ¼ 9) than in the WKY (53.6 + 4.1%, n ¼ 7; Figure 2A ). We further compared the effect of calyculin A on RLC 20 phosphorylation in the permeabilized rat mesenteric arterial smooth muscle of SHR and WKY. We first examined the level of RLC 20 phosphorylation with a total RLC 20 antibody using urea/glycerol gel electrophoresis that separates un-phosphorylated and phosphorylated forms of RLC 20 . As shown in Figure 2B , in permeabilized tissue, during application of pCa 4.5, un-and mono-phosphorylated forms of RLC 20 were detected in both SHR and WKY tissues, but the signal for mono-phosphorylated forms of RLC 20 was stronger in the SHR than in the WKY. Di-phosphorylated forms of RLC 20 were not detected in pCa 4.5. In the case of pCa 9.0 without calyculin A, the total RLC 20 antibody recognized only un-phosphorylated forms of RLC 20 in control SHR and WKY tissues. However, in the presence of calyculin A at pCa 9.0, three bands, un-, mono-, and di-phosphorylated forms of RLC 20 appeared in both SHR and WKY. The amounts of mono-and di-phosphorylated RLC 20 were larger in the SHR than in the WKY.
We also compared agonist-induced di-phosphorylation in intact arterial smooth muscle of SHR and WKY to clarify if the agonist can induce di-phosphorylation and whether agonist-induced di-phosphorylation is augmented in a hypertensive animal model. As shown in Figure 2C , phenylephrine-induced di-phosphorylation of RLC 20 and di-phosphorylated forms of RLC 20 were augmented in the SHR compared with the WKY in intact tissue. We also compared the levels of RLC 20 mono-and di-phosphorylation induced by Ca 2+ -independent, calyculin A in permeabilized rat mesenteric arterial smooth muscle of SHR and WKY using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) with antibodies specific for RLC 20 . As shown in Figure 3 , the results obtained are similar to those seen with urea/glycerol gel electrophoresis. In SHR and WKY, Ser di-phosphorylated RLC 20 ( Figure 3B -di-phosphorylated forms of RLC 20 are stronger in the SHR than in protein-matched samples from the WKY only at pCa 9.0 with calyculin A, but not with pCa 4.5 alone. Finally, we confirmed the expression levels of di-phosphorylated forms of RLC 20 using immunostaining and image analysis with confocal microscopy. As shown in Figure 3C , in SHR and WKY, di-phosphorylated RLC 20 was not detected at pCa 9.0, whereas di-phosphorylated RLC 20 was significantly increased at pCa 9.0 with calyculin A. These results indicate that the contraction induced by calyculin A at pCa 9.0 was accompanied by an increase in monoand di-phosphorylation of RLC 20 .
Identification of the protein kinase involved in the Ca 21 -independent, calyculin A-induced contraction
To identify the nature of protein kinase involved in Ca 2+ -independent, calyculin A-induced contraction and RLC 20 di-phosphorylation, we studied the effects of SM-1, a ZIPK-inhibiting peptide, on the calyculin A-induced contraction and di-phosphorylation of RLC 20 in permeabilized rat mesenteric arterial smooth muscle. As shown in Figure 4A , SM-1 (100 mM) significantly inhibited the amplitude of contraction (31.1 + 9.3%, n ¼ 5) induced by calyculin A at pCa 9.0 ( Figure 4A 2 ) compared with the control group (57.9 + 3.6%, n ¼ 9; Figure 4A 1 ), but scrambled SM-1 had no effect on the calyculin A-induced contraction (57.4 + 7.4%, n ¼ 3; Figure 4A 3 ). SM-1 also significantly inhibited the amount of di-phosphorylation induced by calyculin A ( Figure 4B ).
To confirm the presence of ZIPK in mesenteric arterial smooth muscle, we studied the double immunofluorescence staining of ZIPK and actin or myosin light chain (MLC) in rat mesenteric arterial smooth muscle. As shown in Figure 4C , ZIPK immunoreactivity was verified by co-staining with smooth muscle-specific actin or MLC ( Figure 4C ). The negative control obtained without primary antibodies gave no detectable signal. To determine whether expression of ZIPK changes in SHR animals, we measured the expression of ZIPK in the rat mesenteric artery of SHR and WKY using western blot. We also compared the expression levels of ROCK, CPI-17, and ILK. As shown in Figure 4D , anti-ZIPK detected a prominent band of both 32 kDa and 54 kDa in SHR and a weaker band in protein-matched WKY tissues. Quantification of the immunoblots showed that total (54 + 32 kDa) ZIPK is 1.3 + 0.04-fold (n ¼ 23) more abundant in the SHR than in protein-matched samples from the WKY. ROCK (180 kDa) was detected in both SHR and WKY tissues, and the signal was consistently stronger in the SHR than in the WKY. CPI-17 and ILK were detected in both SHR and WKY tissues at equal expression levels.
Contribution of MYPT1 and CPI-17 phosphorylation to MLCP inhibition during calyculin A-induced contraction in SHR and WKY
We examined whether calyculin A modifies phosphorylation of specific sites on MYPT1 and whether differences in MYPT1 phosphorylation induced by calyculin A exist between SHR and WKY. As shown in Figure 5A , Thr 697 (numbering for rat isoform) phosphorylation of MYPT1 was significantly increased by treatment of SHR and WKY tissue with calyculin A at pCa 9.0 compared with pCa 9.0 alone, and the signal was consistently stronger in the SHR than in the WKY. Quantification of immunoblots for calyculin A (numbering for rat isoform) phosphorylation of MYPT1 was significantly increased by treatment of SHR and WKY tissue with calyculin A in addition to pCa 9.0 conditions, but the phosphorylation levels increased by calyculin A did not differ significantly between SHR and WKY ( Figure 5B) . We also examined the possibility that calyculin A-induced contractions could be a reflection of the CPI-17 phosphorylation status. However, as shown in Figure 5C , phosphorylation levels of CPI-17 increased by calyculin A were not significantly different between SHR and WKY.
Discussion
The present study demonstrates that, in a model of hypertension, there is a significant increase in Ca 2+ -independent, calyculin A-induced contractions. This type of contraction is significantly greater in the SHR than in the WKY, and the augmentation of contractions in the SHR is associated with an increase in mono-and di-phosphorylation of RLC 20 . We also show that ZIPK appears to be the Ca 2+ -independent MLCK involved. We provide evidence that SM-1, a ZIPK-inhibiting peptide, significantly inhibits the contraction and di-phosphorylation of RLC 20 induced by calyculin A at pCa 9.0, that ZIPK is expressed in the mesenteric artery, and that the expression level of ZIPK is higher in the SHR than in the WKY. Finally, we show that the increase in Thr 697 phosphorylation of MYPT1, likely caused by the higher expression levels of ZIPK in SHR, plays an important role in the enhanced calyculin A-induced contraction and RLC 20 phosphorylation in SHR. Taken together, these results suggest that Ca 2+ -independent MLCK activity is enhanced in the SHR and that the increase in the expression level of ZIPK in SHR appears to play an important role in the enhanced calyculin A-induced contraction and RLC 20 phosphorylation.
To investigate the existence of Ca 2+ -independent contraction and di-phosphorylation of RLC 20 in rat mesenteric arterial smooth muscle, we first measured the effects of calyculin A on the contractility of b-escin-permeabilized arterial smooth muscle at pCa 9.0. MLCK is absolutely dependent on Ca 2+ and calmodulin for its activity, and has no activity under these experimental conditions. Thus, in the absence of Ca 2+ (pCa 9.0), we found that there is no phosphorylation of MLC in this system (Figure 2) . However, we also showed that calyculin A induces a gradual increase in force and mono-and di-phosphorylation of RLC 20 in permeabilized rat mesenteric arterial smooth muscle at pCa 9.0. We also showed that the calyculin A-induced contraction is insensitive to treatment with wortmannin, Y-27632, and calphostin-C, ruling out the involvement of traditional MLCK, ROCK, or PKC in this Ca 2+ -independent contraction. These results are consistent with previous reports 8,11 -13,35 and suggest that a Ca 2+ -independent MLCK activity is unmasked in our experimental conditions. To clarify whether the Ca 2+ -independent MLCK activity might be increased in hypertension, we used a model of hypertension, the SHR, and compared Ca 2+ -independent, calyculin A-induced contractions in permeabilized rat mesenteric arterial smooth muscle of SHR and WKY at pCa 9.0. We showed that the amplitude of calyculin A-induced contraction is greater in the SHR than in the WKY. Consistent with this finding, we also showed that in the presence of calyculin A at pCa 9.0, the prevalence of mono-and di-phosphorylated forms of RLC 20 is stronger in SHR than in WKY. In the present study, we measured RLC 20 phosphorylation using three different methods: urea/glycerol gel electrophoresis with a total RLC 20 antibody, SDS/PAGE gel electrophoresis with antibodies specific for RLC 20 , and immunostaining and image analysis with confocal microscopy. Consistent results were obtained with all three methods, and the results indicate that an increase in the amplitude of calyculin A-induced contraction in the SHR is associated with elevations in the mono-and di-phosphorylated forms of RLC 20 .
It is well known that phosphorylation of RLC 20 20 In the present study, to identify the nature of the protein kinase causing the Ca 2+ -independent, calyculin A-induced contraction and RLC 20 di-phosphorylation, we studied the effects of SM-1, a ZIPK-inhibiting peptide, on the calyculin A-induced contraction and di-phosphorylation of RLC 20 . SM-1 significantly inhibited the amplitude of contraction and di-phosphorylation of RLC 20 induced by calyculin A at pCa 9.0; in contrast, scrambled SM-1 had no effect. We also showed that ZIPK is expressed in the rat mesenteric artery, in both the 32 kDa and 54 kDa forms of ZIPK, and that more ZIPK is present in the SHR than in the WKY. It has been shown that a 32 kDa form of ZIPK, expressed in the smooth muscle, co-localizes with actin filaments and plays a role in the regulation of smooth muscle contraction. 37 A 54 kDa form of ZIPK is also expressed in smooth muscle and activated by prostaglandin F 2 a stimulation. 38 Taken together, our results suggest that the increased expression levels of ZIPK in SHR induce augmentation of the calyculin A-induced contraction and RLC 20 phosphorylation. However, in the present study, calyculin A-induced residual contraction in the presence of SM-1, a ZIPK-inhibiting peptide, still exists despite the fact that we used the concentration of SM-1 which is the maximal effective dose. Therefore, ILK might be another possible candidate for Ca 2+ -independent MLCK, although it was detected at equal expression levels in both SHR and WKY tissues in the present study. We found the expression level of ROCK to be stronger in the SHR than in the WKY. Because ROCK can activate ZIPK, ROCK also plays an important role for Ca 2+ -independent MLC phosphorylation.
However, because the ROCK inhibitor Y-27632 had no inhibitory effect on the calyculin A-induced contraction, ROCK might not be a candidate for the Ca 2+ -independent MLCK.
Interestingly, we also found evidence for an effect of ZIPK to phosphorylate MLCP in addition to its apparent direct effect to phosphorylate RLC 20 . It is known that ZIPK can mediate inhibition of MLCP 39, 40 either directly, via phosphorylation of the MYPT1, or indirectly, via phosphorylation of a CPI-17. 41 Therefore, augmentation of di-phosphorylation by calyculin A in the SHR may be due to inhibition of MLCP, either directly, through enhanced phosphorylation of the MYPT1 of MLCP, or indirectly, through enhanced phosphorylation of a CPI-17. To clarify this possibility, we examined the differences of MYPT1 phosphorylation induced by calyculin A between SHR and WKY. We showed that both Thr 697 and Thr 855 phosphorylation of MYPT1 was significantly increased by the treatment of SHR and WKY tissue with calyculin A at pCa 9.0, but the signal of phosphorylation at Thr 697 , and not at Thr 855 , was consistently stronger in the SHR than in the WKY. These results are consistent with the previous finding that ZIPK directly regulates MYPT activity through phosphorylation of Thr 696 (numbering for human isoform and equivalent to Thr 697 ). 42 We also showed that the phosphorylation of CPI-17 was significantly increased by treatment of SHR and WKY tissue with calyculin A at pCa 9.0, and that the increase caused by calyculin A was similar in both SHR and WKY. Taken together, our results suggest that the increase in both Thr 697 phosphorylation of MYPT1 and direct phosphorylation of RLC 20 , driven by the higher expression levels of ZIPK in SHR, plays an important role in the enhanced calyculin A-induced contraction and RLC 20 phosphorylation in this model of hypertension.
In the present study, the SHR have been employed as animal models of human primary (essential) hypertension. Although SHR are widely used as a model to investigate the mechanisms underlying essential hypertension, there are some differences between SHR and human hypertension. Therefore, further study is needed to elucidate the role of Ca 2+ sensitization induced by Ca 2+ -independent MLCK in hypertension using other hypertensive animal models, such as deoxycorticosterone acetate salt-induced hypertensive rats. Investigation is also necessary into whether the increased contractility and di-phosphorylation of RLC 20 induced by Ca 2+ -independent MLCK in hypertension is a causative factor or a consequence of hypertension development. In summary, our results suggest that contraction and phosphorylation of RLC 20 induced by Ca 2+ -independent MLCK activity are further enhanced in the SHR than in the WKY, and ZIPK is a key candidate for causing this effect. Furthermore, the increase in the expression level of ZIPK in SHR appears to play an important role in enhanced calyculin A-induced contraction and RLC 20 phosphorylation.
